<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927888</url>
  </required_header>
  <id_info>
    <org_study_id>SU-05072009-2478</org_study_id>
    <nct_id>NCT00927888</nct_id>
  </id_info>
  <brief_title>Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery</brief_title>
  <official_title>The Effect of Preemptive Sphenopalatine Ganglion Block on Anesthetic Requirements, Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to quantify postoperative pain after functional endoscopic sinus
      surgery (FESS) and investigate whether preemptive analgesia may positively impact
      intraoperative anesthetic management, decrease patient postoperative pain and discomfort, and
      improve patient functional outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sphenopalatine ganglion block (SPGB) with local anesthetic is used to treat facial pain
      and headache of various etiologies and has been widely used during functional endoscopic
      sinus surgery (FESS). The purpose of this study was to investigate whether preemptive SPGB
      may positively impact postoperative pain and functional outcomes after FESS.

      A prospective, double-blind randomized placebo-controlled study was performed. 60 patients
      (18 to 70 yrs), undergoing general anesthesia for bilateral FESS, were randomly assigned to
      receive SPGB with either 2 ml 0.25% bupivacaine with epinephrine 1:100,000 (BP, treatment
      group) or normal saline (NS, control group). SPGB was performed preemptively 10 min before
      the start of surgery. Pre- and post operative (day#0, day#7, day#30) visual analogue pain
      scale, SNOT-20, CT &amp; Endoscopic scores were compared between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain Assessed on Standard VAS Scale</measure>
    <time_frame>VAS Pain Score at 7 days</time_frame>
    <description>Post-operative quality of recovery and pain followed up to 1 month. Visual Analog Pain (VAS) was recorded by the patient on a 10-centimeter line to mark an estimated pain score that could be from zero (0) to ten (10). Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-20 Surgical Outcome Score</measure>
    <time_frame>1-day</time_frame>
    <description>This measures uses a 20 item surgical assessment tool to assess surgical field. This assessment score is the Sino-Nasal Outcome Test, SNOT-20. Patients were completed this validated sinus symptom questionnaire. The average magnitude score for the 20 items is calculated. Each item of the 20-question assessment is scored from 1 to 5 where 1 is less severe and 5 is a maximum as described by that particular symptom score. The final score is reported as a mean with a range of 0 (zero) to 5 (no units).
ref. Otolaryngol Head Neck Surg, 126 (2002), pp. 41-47</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>1 - Bupivacaine Block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline with Epi 1:100,000 (B block)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Block</intervention_name>
    <description>Bupivacaine local anesthesia block prior to start of FESS procedure.</description>
    <arm_group_label>1 - Bupivacaine Block</arm_group_label>
    <other_name>Local Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo is identical in appearance in comparison to active drug.</description>
    <arm_group_label>2 - Placebo</arm_group_label>
    <other_name>Placebo saline injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The study subjects will be 18-70 year old.

          2. The subjects will be American Society of Anesthesiology physical status I and II
             patients.

          3. Patients with chronic rhinosinusitis, presenting for bilateral functional endoscopic
             sinus surgery.

          4. The subjects should understand informed consent and study instructions, AND 5. The
             subjects should not participate in any other research protocols.

        Exclusion Criteria:

          1. Patients with pre-existing chronic facial pain not related to chronic rhinosinusitis.

          2. Patients with pre-existing chronic pain of different etiology.

          3. Patients taking prescription pain medications.

          4. Patients taking antidepressant medications.

          5. Patients taking over-the-counter pain medications within 48 hours of scheduled
             surgery.

          6. Patients in whom oral opioid-containing analgesics would be contraindicated
             postoperatively.

          7. Patients with a known or suspected genetic susceptibility to malignant hyperthermia,
             or known sensitivity to Desflurane or other halogenated agents.

          8. Patients with the history of arrhythmias or significant coronary artery disease.

          9. Patients with psychological disorders.

         10. Patients who are unable to understand the questionnaires or the visual analogue scale
             (VAS) pain scores.

         11. Patients with the history of substance or alcohol abuse.

         12. Patients with compromised renal and liver function.

         13. Patients with abnormal coagulation status or platelet count less than 100,000.

         14. Pregnant patients.

         15. Patients with an allergy to Bupivacaine, Lidocaine or Epinephrine.

         16. Other patients that may be excluded by the investigator, based on medical history and
             physical examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Drover</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cho DY, Drover DR, Nekhendzy V, Butwick AJ, Collins J, Hwang PH. The effectiveness of preemptive sphenopalatine ganglion block on postoperative pain and functional outcomes after functional endoscopic sinus surgery. Int Forum Allergy Rhinol. 2011 May-Jun;1(3):212-8. doi: 10.1002/alr.20040. Epub 2011 Apr 13.</citation>
    <PMID>22287376</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>December 18, 2012</results_first_submitted>
  <results_first_submitted_qc>March 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2015</results_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>David R. Drover</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Stanford medical center</recruitment_details>
      <pre_assignment_details>Having unilateral FESS</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1 - Bupivacaine Block</title>
          <description>Active treatment group with application of bupivacaine block before FESS.</description>
        </group>
        <group group_id="P2">
          <title>Group 2 - Placebo Saline Block</title>
          <description>This group proceeded as per teh active treatment group but with blinded use of saline in the block syringe before start of FESS.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Bupivacaine</title>
          <description>Active treatment group with application of bupivacaine block before FESS.</description>
        </group>
        <group group_id="B2">
          <title>Group 2 - Saline Placebo Group</title>
          <description>Saline substituted in block, placebo treatment group with application of saline block before FESS.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="18" upper_limit="75"/>
                    <measurement group_id="B2" value="42" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B3" value="45" lower_limit="18" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Pain Assessed on Standard VAS Scale</title>
        <description>Post-operative quality of recovery and pain followed up to 1 month. Visual Analog Pain (VAS) was recorded by the patient on a 10-centimeter line to mark an estimated pain score that could be from zero (0) to ten (10). Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>VAS Pain Score at 7 days</time_frame>
        <population>Entire population of both groups.</population>
        <group_list>
          <group group_id="O1">
            <title>1 - Bupivacaine Block</title>
            <description>3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
Bupivacaine Block: Bupivacaine local anesthesia block prior to start of FESS procedure.</description>
          </group>
          <group group_id="O2">
            <title>2 - Placebo</title>
            <description>Normal saline with Epi 1:100,000 (B block)</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain Assessed on Standard VAS Scale</title>
          <description>Post-operative quality of recovery and pain followed up to 1 month. Visual Analog Pain (VAS) was recorded by the patient on a 10-centimeter line to mark an estimated pain score that could be from zero (0) to ten (10). Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Entire population of both groups.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>VAS</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.23"/>
                    <measurement group_id="O2" value="1.12" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SNOT-20 Surgical Outcome Score</title>
        <description>This measures uses a 20 item surgical assessment tool to assess surgical field. This assessment score is the Sino-Nasal Outcome Test, SNOT-20. Patients were completed this validated sinus symptom questionnaire. The average magnitude score for the 20 items is calculated. Each item of the 20-question assessment is scored from 1 to 5 where 1 is less severe and 5 is a maximum as described by that particular symptom score. The final score is reported as a mean with a range of 0 (zero) to 5 (no units).
ref. Otolaryngol Head Neck Surg, 126 (2002), pp. 41–47</description>
        <time_frame>1-day</time_frame>
        <population>Entire study population included.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 - Bupivacaine Block</title>
            <description>Active treatment group with application of bupivacaine block before FESS.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 - Placebo Saline Block</title>
            <description>This group proceeded as per teh active treatment group but with blinded use of saline in the block syringe before start of FESS.</description>
          </group>
        </group_list>
        <measure>
          <title>SNOT-20 Surgical Outcome Score</title>
          <description>This measures uses a 20 item surgical assessment tool to assess surgical field. This assessment score is the Sino-Nasal Outcome Test, SNOT-20. Patients were completed this validated sinus symptom questionnaire. The average magnitude score for the 20 items is calculated. Each item of the 20-question assessment is scored from 1 to 5 where 1 is less severe and 5 is a maximum as described by that particular symptom score. The final score is reported as a mean with a range of 0 (zero) to 5 (no units).
ref. Otolaryngol Head Neck Surg, 126 (2002), pp. 41–47</description>
          <population>Entire study population included.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Score</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.2"/>
                    <measurement group_id="O2" value="1.67" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of enrollment until the 30-day follow-up visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1 - Bupicaine Block</title>
          <description>Active treatment group with application of bupivacaine block before FESS.</description>
        </group>
        <group group_id="E2">
          <title>Group 2 - Saline Placebo Block</title>
          <description>Placebo treatment group with application of saline block before FESS.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Drover, MD</name_or_title>
      <organization>Stanford University</organization>
      <phone>6507250364</phone>
      <email>ddrover@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

